Sunoptic Technologies has acquired LuxteL
Sunoptic Technologies has acquired LuxteL for an undisclosed consideration.
Sunoptic Technologies® OEM Business is focused in four major market segments: medical technology, life science, industrial/machine vision, and dental for product development and manufacturing of fiberoptic and illumination applications. Sunoptics Surgical® provides surgical headlights, Xenon and LED light sources, video cameras, documentation/recording devices, fiber optic cables and other related products. The company was founded 35 years ago and is based in Jacksonville, Florida.
LuxteL's focus in the specialty lighting industry is on a family of ceramic xenon short arc lamps, trademarked CeraLux. These products are more rugged, offer better color rendition and eliminate environmental concerns associated with other lighting techniques.
Oaklins' team in Jacksonville advised the buyer in this transaction.
Talk to the deal team
Related deals
Lindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.
Learn moreEuroHospital Varna has been acquired by Intermedica Group
EuroHospital Varna has been acquired by Intermedica Group, allowing the business to continue to grow and deliver high-quality healthcare services to its patients. Through the transaction, Intermedica Group expands its healthcare presence and intends to build a new model of integrated personalized care focused on preventive, holistic and digital medicine.
Learn moreOlyos Group has acquired a controlling stake in NewScience
Olyos Group has acquired a controlling stake in NewScience from its founders through a transaction structured in two stages, with the strategic objective of ultimately acquiring 100% of the company. The transaction forms part of NewScience’s international growth strategy and a gradual cash-out process for the founder, who intends to complete a full exit. Olyos intends to retain the management team through a put and call option mechanism and an earn-out linked to NewScience’s 2025 EBITDA.
Learn more